Viyash Scientific Limited’s board approved the Viyash Scientific Limited Employee Stock Option Scheme 2026 (VSL ESOP Scheme 2026), pending necessary approvals. The board also approved changes in Senior Management Personnel (SMP) to align with strategic objectives. The decisions occurred during a meeting on February 5, 2026. Several employees are designated as SMPs, effective February 5, 2026.
ESOP Scheme Approved
The board has approved the introduction and adoption of a new employee stock option scheme named “Viyash Scientific Limited Employee Stock Option Scheme 2026” (“VSL ESOP Scheme 2026”), subject to necessary approvals.
Senior Management Changes
Changes in Senior Management Personnel (SMP) were considered and approved by the Board. The leadership roles are realigned to align with the post-merger strategic objectives and operational requirements.
New SMP Designations
The following employees are designated as SMPs, effective February 5, 2026:
- Mr. Attanti Veera Venkata Srinivasa Rao: VP, R&D (API)
- Mr. Nrusimha Srinivasa Rao Bondalapati: VP, Quality & Regulatory
- Mr. Peddanna Gumudavelli: COO, Appco Pharma LLC, Material Subsidiary
SMP Cessation
Mr. Pradip Natarajan will cease to be an SMP, effective February 5, 2026, but will remain employed by the Company.
Audited Financial Results
The Unaudited Standalone and Consolidated Financial Results for Q3 2026 (October-December) and nine months ending December 31, 2025 were considered and approved.
Consolidated Financial Highlights
The consolidated financial results show the following highlights:
- Revenue from operations: ₹8,584.10 million for Q3 2026 and ₹25,003.50 million for the nine-month period.
- Profit before tax: ₹730.70 million for Q3 2026 and ₹2,237.80 million for the nine-month period.
- Total comprehensive income: ₹514.30 million for Q3 2026 and ₹2,261.50 million for the nine-month period.
Standalone Financial Highlights
The standalone results show the following highlights:
- Revenue from operations: ₹3,416.40 million for Q3 2026 and ₹10,095.70 million for the nine-month period.
- Profit before tax: ₹106.10 million for Q3 2026 and ₹674.70 million for the nine-month period.
- Total comprehensive income: ₹229.00 million for Q3 2026 and ₹791.90 million for the nine-month period.
Source: BSE
